Table 2.
Studies enrolling patients with head and neck carcinomas (included primitive skin cancers).
| Published Papers | Target | Treatment | Type of Study | Number of Patients | Responses (ORR) |
|---|---|---|---|---|---|
| Acta Derm Venereol | Skin cancer | ECT | Retrospective trial | 33 | 100% |
| 2019. 1; 99(13): 1246–1252. | |||||
| Bonadies et al. [50] | |||||
| Head Neck 2019; 41(2): 329–339. | SCCHN | ECT | Phase II | 26 | 58% |
| Plaschke et al. [51] | |||||
| Eur J Cancer 2017 Dec; 87: 172–181. | SCCHN | ECT | Phase II | 36 | 56% |
| Plaschke et al. [52] | |||||
| J Transl Med 2017 Apr 26;15(1):82. | Skin cancer | ECT | Retrospective trial | 22 | 81.8% |
| Di Monta et al. [53] | |||||
| Ann Surg 2012 Jun;255(6):1158–64. | Skin cancer | ECT | Phase II trial | 25 | 100% |
| Gargiulo et al. [54] | |||||
| Oral Oncol. 2019 May; 92: 77–84. | SCCHN and Skin cancer | ECT | Retrospective trial | 93 | 45% |
| Longo et al. [45] | |||||
| Dermatol Surg. 2010 Aug; 36(8): 1245–50. | Skin cancer | ECT | Retrospective trial | 6 | 83% |
| Landstrom et al. [55] |